Treatment of ITP in Children Under 18 with Mucosal Bleeding or Reduced Quality of Life
Clinical Scenario
This protocol is for paediatric patients — children under 18 years of age — diagnosed with immune thrombocytopenia (ITP) who present with non-life-threatening mucosal bleeding and/or a measurable reduction in health-related quality of life.
Defining features: Age under 18, ITP with non-life-threatening mucosal bleeding and/or diminished health-related quality of life.
Treatment Approach
At this stage of the escalation pathway, management centres on a surgical intervention. Guidance emphasises delaying this procedure for as long as possible after diagnosis, given the recognised potential for spontaneous remission in the period following initial presentation.
The complete regimen — including the full escalation sequence, specific indications, and decision criteria — is available in the structured protocol.
References
- In children with newly diagnosed ITP who have non-life-threatening mucosal bleeding and/or diminished health-related quality of life, the ASH guideline panel suggests corticosteroids rather than intravenous immunoglobulin or anti-D immunoglobulin.
- Splenectomy
- If possible, splenectomy should be delayed as long as possible after diagnosis because of the potential for spontaneous remission in the first year.
View source ↗